官宣9款医疗险覆盖商保创新药后又撤销，复星联合健康保险缘何“悔棋”

Core Viewpoint - The announcement by Fosun United Health Insurance regarding the inclusion of nine medical insurance products in the commercial health insurance innovative drug directory was retracted shortly after its release, raising questions about the internal decision-making process and the implications for the health insurance market [3][4][6]. Group 1: Announcement and Withdrawal - The initial announcement highlighted that Fosun United Health Insurance would cover nine innovative drugs in its medical insurance products, generating excitement in the industry [3][5]. - The announcement was later deleted from the company's official WeChat account, indicating a lack of finalized discussions regarding the products [4][5]. - The company stated that the adjustment to the drug list would take effect from January 1, 2026, for specific insurance products [5]. Group 2: Market Implications - The release of the first commercial health insurance innovative drug directory, which includes 19 high-value drugs, is seen as a potential opportunity to enhance the purchasing rate of commercial insurance [7]. - The directory aims to address the challenges of high-priced innovative drugs and improve the collaboration between insurance companies and pharmaceutical firms [7][8]. - Experts believe that integrating innovative drugs into medical insurance can significantly reduce patients' financial burdens and enhance the competitiveness of insurance products [6][7]. Group 3: Challenges and Considerations - The main challenges for insurance companies include high drug prices leading to increased claims costs and the lack of historical data for accurate pricing [8][9]. - Companies are encouraged to develop specialized products and collaborate with pharmaceutical companies to create data-sharing and risk-sharing mechanisms [8][9]. - The success of integrating innovative drugs into insurance offerings depends on effective risk management and sustainable business practices [7][9]. Group 4: Company Background and Financial Performance - Fosun United Health Insurance, established in January 2017, is the sixth approved professional health insurance company in China, with major shareholders including Fosun Pharma and the International Finance Corporation [10][14]. - The company has shown a clear upward trend in profitability since 2021, with net profits of 0.20 billion, 0.63 billion, 0.23 billion, and 0.42 billion from 2021 to 2024 [12][13]. - Recent capital increases have been approved, enhancing the company's capital strength and solvency, which is crucial for covering innovative drugs and supporting business expansion [13][14].